What question did this study set out to answer?

The aim is to develop a comprehensive organotypic model that mimics ovarian cancer characteristics for therapy testing.

April 19, 2026Cancer Research

Abstract LB248: Development of organotypic patient-derived ovarian cancer model for therapy testing

View Full Paper

Ask AI

Bookmark

The aim is to develop a comprehensive organotypic model that mimics ovarian cancer characteristics for therapy testing.
Utilized tumor sections from five high-grade serous ovarian carcinoma donors.
Established cultures using OrganoPlate Graft UF platform with tumor tissue, cancer-associated fibroblasts, and endothelial cells.
Characterized models through immunostaining and cytokine analysis.
Models exhibited varying tumor-stroma ratios and immune infiltration levels.
Chemotherapy treatments showed different responses across donors, revealing effects on tumor clusters and surrounding supportive cells.
The 3D model demonstrated enhanced chemoresistance compared to conventional 2D cell lines.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Develops a patient-derived model to evaluate therapy responses in ovarian cancer, suggesting enhanced predictive capabilities over traditional methods.

Cite This Study

Schilt et al. (2026) studied this question.

synapsesocial.com/papers/69e473de010ef96374d8fa5e https://doi.org/10.1158/1538-7445.am2026-lb248

View Full Paper

Ask AI

Bookmark

Implication

Develops a patient-derived model to evaluate therapy responses in ovarian cancer, suggesting enhanced predictive capabilities over traditional methods.

Abstract LB248: Development of organotypic patient-derived ovarian cancer model for therapy testing

Key Points

Discussion

Implication

Cite This Study

Abstract LB248: Development of organotypic patient-derived ovarian cancer model for therapy testing

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider